Clinical Trial Update: Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome [Phase 2]

View source ↗

Summary

Phase 2 open-label safety and tolerability study of NBI-98854 in pediatric Tourette syndrome completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2022-02-23